GCM
JAZZ icon

Gladius Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Gladius Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-290
Closed -$32.3K – 160
2024
Q3 		$32.3K Sell
290
-19
-6% -$2.08K ﹤0.01% 197
2024
Q2 		$33K Buy
+309
New +$34K ﹤0.01% 206
2022
Q3 		– Sell
-210
Closed -$33K – 439
2022
Q2 		$33K Buy
+210
New +$32.3K ﹤0.01% 293

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Gladius Capital Management's JAZZ Position: Q4 2024 in Review

Gladius Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 290 shares — an estimated $32.3K sold.

Gladius Capital Management first reported a position in JAZZ in Q2 2022 and held it in 3 quarters. The position peaked at $33K in Q2 2022. 509 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Gladius Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Gladius Capital Management sold 290 Jazz Pharmaceuticals shares in Q4 2024, an estimated $32.3K.
  • Gladius Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Gladius Capital Management's Jazz Pharmaceuticals position peaked at $33K in Q2 2022.
  • 509 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.